Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Terminated 2Unknown 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 211Thoracic 72Head & Neck 25Other solid neoplasm 13Gynecologic 13Lymphoid 10Breast 8Tumor-Agnostic 7CNS 6Sarcoma 4Genitourinary 4Endocrine 3Other neoplasm 2NET 2Dermatologic 2Myeloid 1

Conditions

Sarcoma 2Osteosarcoma 1Hemangiosarcoma 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 215Cyclophosphamide 210Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Irinotecan 79Magnetic Resonance Spectroscopy 78pembrolizumab 75Radiation 66Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 44Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × sintilimab × Sarcoma × Clear all
NCT05026736 2025-08-17

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled
Sarcoma

Hemangiosarcoma

NCT04589754 2024-01-02

Adriamycin and Ifosfamide Combined With Sintilimab

Sun Yat-sen University

Phase 2 Recruiting
176 enrolled
Sarcoma

Sarcoma

NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
9 enrolled
SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

NCT04356872 2020-07-14

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Fudan University

Phase 2 Unknown
45 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡